p21 anticorps
-
- Antigène Voir toutes p21 (CDKN1A) Anticorps
- p21 (CDKN1A) (Cyclin-Dependent Kinase Inhibitor 1A (p21, Cip1) (CDKN1A))
-
Reactivité
- Humain
-
Hôte
- Souris
-
Clonalité
- Monoclonal
-
Conjugué
- Cet anticorp p21 est non-conjugé
-
Application
- Western Blotting (WB), Immunofluorescence (IF), Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
- Specificité
- Does not react with mouse and rat
- Purification
- Protein G affinity chromatography
- Immunogène
- Recombinant full-length human protein was used as the immunogen for the p21 antibody.
- Clone
- CIP1-823
- Isotype
- IgG2a kappa
- Top Product
- Discover our top product CDKN1A Anticorps primaire
-
-
- Indications d'application
-
Flow Cytometry: 0.5-1 μg/million cells in 0.1ml
Immunofluorescence: 1-2 μg/mL
Western Blot: 1-2 μg/mL
Immunohistochemistry (FFPE): 2-4 μg/mL for 30 min at RT (1)
Prediluted format : incubate for 30 min at RT (2)
Optimal dilution of the p21 antibody to be determined by the researcher.1. Staining of formalin-fixed tissues requires boiling tissue sections in 10 mM Citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 min
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min. - Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- 0.2 mg/mL
- Buffer
- PBS with 0.1 mg/mL BSA and 0.05 % sodium azide
- Agent conservateur
- Sodium azide
- Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Stock
- -20 °C
- Stockage commentaire
- Aliquot and Store at -20C. Avoid freez-thaw cycles.
-
- Antigène
- p21 (CDKN1A) (Cyclin-Dependent Kinase Inhibitor 1A (p21, Cip1) (CDKN1A))
- Autre désignation
- p21 (CDKN1A Produits)
- Synonymes
- anticorps CCND1, anticorps CDKN1A, anticorps CAP20, anticorps CDKN1, anticorps CIP1, anticorps MDA-6, anticorps P21, anticorps SDI1, anticorps WAF1, anticorps p21CIP1, anticorps CDKI, anticorps Cdkn1, anticorps Waf1, anticorps mda6, anticorps p21Cip1, anticorps p21WAF, anticorps Cip1, anticorps UV96, anticorps p21, anticorps cip1, anticorps p16Xic2, anticorps sdi1, anticorps waf1, anticorps cap20, anticorps cdkn1, anticorps mda-6, anticorps p21cip1, anticorps si:ch1073-48m5.2, anticorps KRAS2, anticorps p21ras, anticorps cyclin D1, anticorps cyclin dependent kinase inhibitor 1A, anticorps cyclin-dependent kinase inhibitor 1A (P21), anticorps cyclin-dependent kinase inhibitor 1A, anticorps cyclin-dependent kinase inhibitor 1A L homeolog, anticorps cyclin-dependent kinase inhibitor 1, anticorps KRAS proto-oncogene, GTPase, anticorps CCND1, anticorps CDKN1A, anticorps Cdkn1a, anticorps cdkn1a.L, anticorps cki1, anticorps cdkn1a, anticorps KRAS
- Sujet
- This mAb recognizes a 21 kDa protein, identified as the p21WAF1 tumor suppressor protein. This mAb is highly specific to p21 and shows no cross-reaction with other closely related mitotic inhibitors. p21WAF1 is a specific inhibitor of cdk s and a tumor suppressor involved in the pathogenesis of a variety of malignancies. The expression of this gene acts as an inhibitor of the cell cycle during G1 phase and is tightly controlled by the tumor suppressor protein p53. Its expression is induced by the wild type, but not mutant, p53 suppressor protein. Normal cells generally display a rather intense nuclear p21 expression. Loss of p21 expression has been reported in many carcinomas (gastric carcinoma, non-small cell lung carcinoma, thyroid carcinoma).
- ID gène
- 1026
- UniProt
- P38936
- Pathways
- Signalisation p53, Signalisation PI3K-Akt, Cycle Cellulaire, AMPK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Mitotic G1-G1/S Phases, DNA Replication, Hepatitis C, Synthesis of DNA, Autophagy
-